Alfonso Illiano

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Oncology, Standard Chemotherapy, Randomised Phase 3 +8

Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group

Cesare Gridelli, Ciro Gallo, Frances A. Shepherd et al. · Journal of Clinical Oncology · 2003 · 245 citations

Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer

Lucio Crinò, Giuseppe Bronte, Paolo Bidoli et al. · Lung Cancer · 2019 · 154 citations

Neuro-oncology, Brain Metastases, Medicine +7

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

Francesco Passiglia, Federico Cappuzzo, Oscar Alabiso et al. · British Journal of Cancer · 2018 · 85 citations · Full text

EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non–small cell lung carcinoma patients

Umberto Malapelle, Claudio Bellevicine, Caterina De Luca et al. · Cancer Cytopathology · 2013 · 80 citations · Full text